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Abstract 
There is a dearth of scholarship on the notion that chronic or severe physical illness can be the 
threshold issue in the development of mental illness and chemical dependency.  In a random 
sample of 300 participants in a hospital based mental health clinic, research was conducted to 
determine whether relationships exist among the three domains:  physical illness, mental illness, 
and chemical dependency.  Research found strong relationships among chronic illnesses, such as 
Hepatitis C, substance use disorders (SUDs), and various Axis I and Axis II mental health 
diagnoses.  Research further suggests that pain, whether due to a general medical condition, or to 
an accident or injury is related to opioid use disorders and Axis I mental health disorders.  
Finally, research suggests that stomach and intestinal issues have a strong relationship to alcohol 
use disorders and Axis I and Axis II mental health disorders.  The research suggests that 
counselors should pay close attention to Axis III medical conditions as developmental issues that 
may be related to the onset of mental illness and SUDs.
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The Relationship Between Physical Illness, Mental Illness and Chemical Dependency 
 Significant research has been conducted into, what has been deemed by mental health 
service providers as, “co-occurring” or “dual diagnosis” of co-morbid mental health issues and 
substance use disorders (SUDs).  In addition, significant research has been conducted by both the 
mental health scholarly community and the medical community into the relationship between 
both physical illness and mental health, and physical illness and SUDs.  Little research has been 
conducted with respect to the relationship of physical illness, as the threshold issue for the 
development of mental illness and/or SUDs.  While this study does not purport to answer the 
question of whether physical illness is such a threshold issue, it does suggest initial empirical 
evidence that links the three classes of disorders. 
 The mental health delivery system is dominated by mental health counselors, social 
workers, and psychologists, none of which are medical doctors.  As such, when clients come in 
for mental health services, it is rare that medical diagnoses are discovered at the time of 
evaluation, unless the client is forthright in their medical history, or unless the mental health 
practitioner spends a significant amount of time discussing medical conditions.  While most 
mental health evaluations include a brief medical history, rarely do clinicians discuss history and 
onset of physical illness as part of the overall mental health diagnostic impression.  As such, 
mental health counselors and other mental health providers are unable to determine whether 
physical illness is the threshold issue that causes an individual to develop mental distress or 
SUDs.  If mental health professionals had better insight into the originating factors that led to the 
development of mental illness and/or SUDs, it is possible that alternative treatment protocols 
would be beneficial. 
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 The purpose of this research was to determine whether relationships exist between 
medical illnesses, mental health issues, and SUDs.  This research is significant because it may 
provide mental health practitioners with greater insight into the developmental reasons that 
individual clients develop mental health symptoms or SUDs.  This research is also significant 
because it may lead to the development of innovative treatment modalities that emphasize the 
specific threshold that has led to the development of mental illness and SUDs.  Absent a clear 
understanding of the client’s physical illness, including type of illness, severity of illness, effect 
of illness on quality of life, and date of onset of illness, mental health practitioners are basing 
diagnostic impressions on only one part of the individual.  Obtaining additional information 
about physical illnesses would allow the mental health community to treat clients more 
holistically, and may allow mental health counselors to free themselves of some of the rigidity 
found in the DSM-IV.  Physical illness and its effects on quality of life may presuppose mental 
health diagnostic criteria, freeing the mental health professional to pursue different diagnostic 
and treatment regimen. 
 The research question giving rise to this study is:  What is the prevalence of mental health 
diagnoses, substance use disorders and physical illness?  The method involved in this study was 
a retrospective medical record review of 300 current clients with an active Axis I or Axis II 
mental health diagnosis at a hospital-based mental health clinic in suburban Western New York.  
The researcher reviewed each file, coding the mental health diagnosis, initially excluding SUDs 
alone.  The researcher then reviewed each file for SUDs, coding separately for each substance.  
Finally, the researcher reviewed the files, looking for evidence of an Axis III medical diagnosis, 
coding for specific chronic or severe illnesses.  Limitations to this study included the inability of 
the researcher to determine the date of onset of physical illnesses, the effects the physical illness 
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had on participant quality of life, and the current status of remission of either physical illness or 
SUDs because the researcher relied solely on medical records and had no direct contact with the 
participants. 
 The researcher’s frame of reference is based upon the notion that most mental health 
issues and SUDs are born out of a developmental issue that occurred during an individual’s 
lifespan.  While there are many developmental issues that may trigger mental health issues or 
SUDs, the researcher in this study was particularly interested in physical illness as the threshold 
issue.  As such, the researcher assumed that the sudden onset of a physical illness may play a 
significant role in the development of mental health issues and SUDs. 
 While this study in no way proves that physical illness is a threshold issue to the 
development of mental illness and/or SUDs, it does provide initial empirical evidence suggesting 
that significant relationships exist among all three domains.  Additional research may provide 
empirical evidence supporting the notion that physical illness is the threshold issue for some 
individuals; however, the limitations in the present study preclude such a conclusion. 
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Review of the Literature 
 Individuals with mental health disorders and chemical dependency have long been 
labeled as having a “dual diagnosis” or a “co-occurring disorder” (Council on Accreditation of 
Counseling and Related Professions [CACREP], 2009; Xie, Drake, McHugo, Xie, & Mohandas, 
2010).   Rarely have researchers or practitioners opined that severe or chronic physical illness 
impacts the onset of such “dual” or “co” diagnoses.  The onset of chronic or severe illness can 
occur at any time during one’s developmental lifespan, and may effect have a significant impact 
on one’s developmental process.  There is a significant body of research suggesting a 
relationship between mood and personality disorders with substance use disorders, and 
substantial literature suggesting a connection between severe or chronic physical illness with 
emotional disorders.  There is also significant literature on co-occurring physical disorders and 
chemical dependency.  Counselors should be aware of the potential interaction among physical, 
emotional, and chemical disorders because of the interrelation that one disorder has on the 
others.  Physical illness has the potential to give rise to both mental health disorders and 
chemical dependency disorders.  While counselors are not physicians, it is imperative that 
counselors be informed on clients’ physical illnesses at the onset of the counseling relationship 
so that counselors can execute best practices for treatment.   There is a significant gap in the 
literature as it relates to chronic or severe physical illness as the threshold incident leading to the 
onset of both severe mental illness and chemical dependency.    
Co-occurring Mental Health Disorders and Substance Use Disorders 
 The most common use of the terms “co-occurring disorders,” and “dual diagnosis” relates 
to the combination of mental health disorders and substance use disorders.  Such co-occurring 
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disorders seem to appear most often in mood disorders, followed by personality disorders, and 
then thought disorders. 
 Mood disorders and substance use disorders. Mood disorders such as Major 
Depressive Disorder (MDD) and Substance Use Disorders (SUD) are perhaps the most 
researched and reported of all co-occurring disorders, leading to perhaps the most heterogeneous 
results.  Conner, Pinquart, and Duberstein (2008) highlighted 55 studies in their meta-analysis 
indicating that depression is associated with substance use.   Various commonly used instruments 
in measuring depression were compared for validity and reliability in determining a correlation 
between SUDs and MDD.  Results indicated that 55% of participants involved in the studies had 
above average levels of depressive symptoms (Conner, 2008).    There were somewhat consistent 
findings of 39% comorbid SUDs and MDD in a study of 2,541 patients enrolled in a study to 
determine the efficacy of the Sequenced Treatment Alternatives to Relieve Depression 
(STAR*D; Davis et al. 2005).  The goal of STAR*D, which is a multivariate treatment protocol 
for depression, is to determine the best treatment alternatives for people who did not respond 
well to traditional medications, such as SSRIs (Davis et al., 2005).  
 Participants in the Davis et al. (2005) study ranged in age from 18-75 years and had been 
diagnosed with non-psychotic MDD.  Those with additional diagnoses of schizoaffective 
disorder, schizophrenia, bipolar disorder, anorexia nervosa, bulimia, and obsessive-compulsive 
disorder were screened out of the study due to the necessity of different treatment regimens.  Of 
the 2,541 participants, more than 41% of all participants had co-occurring MDD and SUD; 
specifically, 23.6% reported symptoms of concurrent MDD and alcohol use disorder, 11.2% had 
MDD and an illicit drug use disorder, and 5.3% had MDD and both alcohol use and drug use 
disorders.  
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 Dyer and Cruickshank (2005) found that 35% of the 368 methamphetamine users they 
surveyed met the diagnostic criteria for MDD.  Within that same study, the researchers divided 
the participants into groups, a poly-substance group and an individual substance group. 
Participants, who used both methamphetamine and heroin, had higher mean Beck Depression 
Indices (Beck, Steer & Brown, 1997) than those who used only heroin or methamphetamine 
(Dyer & Cruickshank, 2005).  The results suggested that people with poly-substance disorders 
have higher rates of depression than those with individual SUDs, which is in contrast to Davis et 
al.’s (2005) findings of a significantly lower rate of depression in poly-substance users. 
 In one study, the rate of co-occurring MDD and SUDs for adolescents was consistent 
with adult populations (Subramaniam, Lewis, Stitzer, & Fishman, 2002).  Fifty-six adolescents 
in a residential chemical dependency treatment program reported using multiple substances at 
least three times per week in the six months prior to treatment admission. The most common 
substances included marijuana (86%), alcohol (69%), cocaine (25%), and opiates (11%).  Gender 
was a clinically significant factor among adolescents with depression, with females displaying 
significantly higher levels than males. Subramaniam et al.’s findings were in contrast to the 
Davis et al. (2005) study, wherein females were less likely to present with depressive symptoms.  
Davis et al. found that 39.6% of males and 23.2% of females with SUDs presented with 
depressive symptoms (Davis et al. 2005). 
 There are several additional indicators of increased levels of depressive symptoms 
associated with substance abuse.  Research found that individuals who shared needles in 
intravenous drug use had higher levels of depressive symptoms (Conner, 2008).  Additionally, 
those who reported previous suicide attempts had higher levels of concurrent depressive 
symptoms and substance abuse (Davis et al. 2006).   
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 Distinguishing between primary and secondary disorders. There is a significant body of 
research alone on the effects of depression on addiction relapse and vice versa.  As noted by 
Curran, Booth, Kirchner, & Deneke (2007), much of the research devoted to treatment outcomes 
does not distinguish whether the symptoms of depression are primary MDD, or substance 
induced MDD.  Few data aimed at determining the source of one’s depression have been 
collected.  The literature that is available leads to differing opinions as to the nature of co-
occurring depression and substance use. 
   As with any co-occurring mental health and substance use disorders, researchers disagree 
on the order of disease onset, progression and treatment (Nunes & Rounsaville, 2006).  One of 
the predominant issues in making this determination is the terminology afforded by the DSM-IV.  
Nunes and Rounsaville (2006) suggested that the inclusion of primary disorders and substance 
induced disorders create significant confusion for the practitioner because those disorders that 
are categorized as substance induced should ‘”exceed the usual effects”’ of substances, implying 
something more (p. 91).  Even the writers of the DSM-IV hypothesized that a “substance 
induced” mood disorder is not merely a condition created by the substance, but rather a mood 
disorder that is either triggered or exacerbated by substance use.  In contrast, one research group 
has interpreted the DSM-IV as considering a mood disorder as “primary” and not “substance 
induced” if the symptoms predate the individual’s substance use, exceed that of the substance 
alone, or continue for at least four weeks beyond acute substance (Niciu  et al. 2009). 
 Niciu et al. (2009) compared four groups of participants labeled as substance users:  those 
with no history of Major Depressive Episode (MDE), those with an independent diagnosis of 
MDE, those diagnosed with substance induced MDE only, and those diagnosed with both 
independent and substance induced MDE.  Of the 1929 participants in the study, 168 reported 
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MDE that was both “independent” and “substance induced.” Of these participants, 45.4% (n = 
74) reported their first MDE as “substance induced,” while 50.9% (n = 83) reported their first 
episode of MDE independent of substance use, and 3.7% (n = 6) reported the onset of MDE 
concurrent with their substance use (Niciu et al. 2009).  The research team used a more stringent 
definition of MDE than that used in the DSM-IV, requiring that participants meet the full criteria 
for MDE and not the more generalized criteria for substance induced MDE.  Those participants 
who identified as having both independent and substance induced MDE “fared much worse on a 
variety of psychopathological measures,” which suggested that the distinction between primary 
MDE and substance induced MDE is “inadequate to characterize depressive episodes among 
substance-dependent individuals (Niciu et al. 2009, p. 1706).” 
 Treatment interventions for mood and substance use disorders. Perhaps the most 
significant notion of co-occurring MDD and SUD involves the likelihood for substance relapse 
after partial or total substance-use remission.  Curran et al. (2007) found moderate to severe 
symptoms of depression at the time of discharge from a substance abuse detoxification center to 
be a valid predictor of substance relapse within three months.    Of the 126 consecutive 
admission participants studied, 70% of those who scored high on the Beck Depression Inventory 
(Beck, Steer, & Brown, 1996) at the time of release relapsed within the three month period. The 
researchers found, however, that only 40%, of those participants who left the clinic with a 
prescription for antidepressant medication, relapsed in the same period. The researchers 
concluded that medication management of depressive symptoms helped to reduce relapse rates.  
Non-pharmaceutical based treatment has yielded similar or even more impressive results.  
 Researchers used Mindfulness Based Relapse Prevention (MBRT) to prevent relapse, 
through reducing depressive symptoms and craving, with a sample of 168 participants who were 
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enrolled in outpatient substance abuse treatment (Witkiewitz & Bowen, 2010). The researchers 
used the Beck Depression Inventory and the Penn Alcohol Craving Scale (Flannery, Volpicelli & 
Pettani, 1999).  The use of MBRT mediated depressive symptoms in nearly 73% of the 
participants, which predicted longer treatment adherence and better treatment outcomes 
(Witkiewitz & Bowen, 2010).   
 Treatment retention variables. Treatment retention for those diagnosed with both MDD 
and SUD are impacted by several variables.  Two of the more noteworthy variables suggesting 
lower treatment adherence are age and racial minority (Tate et al. 2011).  In a study of 253 
participants, recruited from the Department of Veterans Affairs in San Diego, researchers found 
“immutable predisposing characteristics (specifically age and race)” that were related to lower 
treatment attendance and higher treatment dropout (Tate et al. 2011 at p. 362).  Researchers had 
various theories as to why there were disproportionately high dropout rates among these groups.  
Despite the varying theories, researchers agreed that new options such as computer-based 
interventions be used for younger participants, and individually delivered treatment interventions 
for minority groups (Tate et al. 2011).  
 Personality disorders and substance use disorders. Evidence-based research found a 
strong correlation between co-occurring diagnoses of personality disorders and substance use 
disorders.  Personality disorders are defined as “patterns of maladaptive responses related to 
one’s perceptions, cognitions, emotional range/reactivity, or impulse control” (Taylor, 2005, p. 
516). It should be noted that research on personality disorders, particularly those classified as 
“Cluster C” personality disorders are difficult to  interpret due to the symptom similarity to Axis 
I diagnoses of depression and anxiety (Bowden-Jones  et al., 2004).  Moreover, evidence 
suggests that individuals with “Cluster B” personality disorders, particularly Anti-social 
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Personality Disorder (ASPD) and Borderline Personality Disorder (BPD) are at significantly 
higher risk for substance use disorders due to some of the characteristics of personality disorder, 
such as impaired decision-making processes, anti-social behavior, and difficulties in forming 
meaningful relationships (Bowden-Jones et al., 2004; Taylor, 2005; Westermeyer & Thuras, 
2005). 
 Bowden-Jones et al., (2004) studied 278 individuals admitted for substance abuse 
treatment.  Of these participants, 113 were also diagnosed with a personality disorder based on 
personality subtype and cluster.  The purpose of the study was to determine the prevalence and 
type of personality disorder co-occurring with SUDs (Bowden-Jones et al., 2004).  The 
participants were generally categorized by substance used:  those with alcohol use disorders, and 
those with drug use disorders.  Initial findings showed that 37% of those with drug use disorders 
had a co-occurring personality disorder, with by far the highest prevalence in “Cluster B” 
disorders such as anti-social and borderline personality disorders (Bowden-Jones, 2004).   Those 
with alcohol disorders were also more likely to have “Cluster B” disorders, but were also found 
to have a significant number of “Cluster C” disorders, including Obsessive-compulsive Disorder 
(OCD) and Dependent Personality Disorder (DPD). 
 ASPD and substance use disorders. Taylor (2005) opined that persons with “Cluster B” 
personality disorders and persons with SUDs share some similar personality characteristics.  
Specifically, both groups tend to have deficits in certain cognitive functioning, such as impaired 
judgment, poor planning, and impulsivity.  She further suggested that such deficits may have led 
to excessive drug and alcohol use, despite negative consequences (Taylor, 2005).  Westermeyer 
and Thuras (2005) found similar deficits in a sample consisting of individuals with SUDs and 
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ASPD, revealing that participants with co-occurring SUD and ASPD engage in more use of 
illicit drugs. 
 A study consisted of 123 college students who were administered several inventories to 
evaluate cognitive functioning (Taylor, 2005).  Participants were also screened for Axis I SUDs 
using the Structured Clinical Interview for DSM-IV (First, Spitzer, Gibbon, & Williams, 2001), 
and for Axis II personality disorders using the Structured Interview for DSM-IV Personality 
Disorders (Pfohl, Blum, & Zimmerman, 1995).  Only those participants who screened positive 
for both SUD and Cluster B personality disorders were included in the study (Taylor, 2005).  Of 
the participants, 18.2% were diagnosed with ASPD; this group had a significant correlation to 
drug use beyond cannabis and/or alcohol, suggesting that persons with ASPD progress in their 
substance use to drugs such as cocaine, heroin, and methamphetamines.   
 A study (Westermeyer & Thuras, 2005) of 606 participants with SUDs, 54 of which were 
also diagnosed with ASPD, found that persons with ASPD averaged 6.2 more symptoms of SUD 
than those without ASPD.  Participants were categorized as having ASPD if they met the DSM-
IV criteria for ASPD.  Participants were then administered the Interviewer-Rated Minnesota 
Substance Abuse Problem Scale (Westermeyer, Nugent, & Crosby, 1998) to determine degree of 
and associated problems with substance abuse. Significantly, in both the Taylor (2005) and the 
Westermeyer & Thuras (2005) studies, participants with ASPD identified interpersonal conflict 
management, negative life situations, family discord, and legal problems as significant triggers to 
substance use. 
 BPD and substance use disorders.  Significant correlations between SUDs and BPD 
have been found (Bowden-Jones et al., 2004; Taylor, 2005; Westermeyer & Thuras, 2005).  The 
prevalence of BPD in the general population is approximately 2% (APA, 2000).  In the drug 
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using population, rates of BPD vary from 11% to 65% (Darke et al., 2007).  Symptoms 
associated with BPD include feelings of emptiness, impulse and anger control, and intense and 
frequent mood changes (APA, 2000; Darke et al., 2007). 
 In a 36-month study, 29 heroin users were evaluated for drug treatment history, overdose 
history, and suicide history.  They were also screened for drug use history, including needle 
sharing, health related problems, and criminal behavior.  Among those diagnosed with BPD (n = 
186), only 8.2% of the cohort achieved sustained heroin abstinence over the 36-month period, 
which represents “a persistently elevated risk…compared to other heroin users” (Darke et al., 
2007 p. 1144).  Those with BPD also continued to show higher levels of risky behavior after they 
stopped using heroin.  Continued legal problems, health-related issues, and treatment adherence 
remained considerably higher with those participants dually diagnosed with BPD and SUD 
(Darke et al., 2007). 
 Zanarini et al. (2010) found both similar and contrasting results to previous findings 
associated with co-morbid BPD and SUD.  In a ten year follow-up study of 290 participants, 
researchers found that persons diagnosed with BPD were two times more likely to have a 
substance use disorder than an alcohol use disorder, which substantiates earlier data from 
Bowden-Jones et al. (2005).  Furthermore, several researchers (Bowden-Jones et al., 2004; 
Taylor, 2005; Westermeyer & Thuras, 2005) found that SUDs were “significantly more common 
among borderline patients than among [other] Axis II comparison participants (Zanarini et al. 
(2010).  Overall, participants with BPD were 65% more likely to have substance-related 
disorders, while 52% were more likely to have alcohol-related disorders (Zanarini et al., 2010).  
 Treatment of personality disorders and SUDs. One area studied by Zanarini et al. 
(2010), which was not considered by previous studies, involved rates of relapse in the co-
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occurring BPD/SUD population.  Among the participants, 40% of BPD participants with alcohol 
dependence, who relapsed, ultimately experienced another period of alcohol dependence.  
Similarly, 35% of BPD participants with drug dependence, who relapsed, ultimately experienced 
another period of drug dependence (Zanarini et al., 2010).  
 Considering the high rates of co-occurring “Cluster B” personality disorders and SUD, it 
is important to consider some of the reasons behind increased substance use.  As described 
above, some of the characteristics of “Cluster B” personality disorders include interpersonal 
conflict management, negative life situations, family discord, and legal problems as significant 
triggers to substance use (APA, 2000).  Smyth and Wiechelt (2010) confirmed some of these 
findings and identified additional triggers common to persons with “Cluster B” personality 
Disorders.   
 In a study of 50 participants in an inpatient substance abuse treatment facility, researchers 
divided the cohort into those presenting with a personality disorder and those who did not.  
Researchers determined that 62% of the participants met the criteria for at least one personality 
disorder (Smyth & Wiechelt, 2010).   Researchers discovered several significant findings.  
Initially, those with personality disorders had significantly higher drug screening scores, 
suggesting higher levels of dependence.  Moreover, analysis of the research suggested that those 
with personality disorders were more likely to use drugs when experiencing “unpleasant 
emotions, physical discomfort, and conflict with others” (p. 69).  Their findings supported 
previous findings (Taylor, 2005; Westermeyer & Thuras, 2005) that conflict management was a 
common trait among those with co-morbid SUDs and “Cluster B” personality disorders.  
Furthermore, Smith and Wiechelt (2010) suggested that those with personality disorders have 
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lower self-efficacy for remaining abstinent under pressure from others, indicating a higher 
likelihood for substance relapse. 
 Finally, most researchers agreed that specific modes of follow-up are a necessary element 
to treatment of co-occurring SUD and personality disorder (Jansson, Hesse, & Fridell, 2008; 
Smyth & Wiechelt, 2010; Zanarini et al., 2010).  Both Smyth and Wiechert (2010) and Zannarini 
et al. (2010) suggested that Dialectical Behavioral Therapy (Linehan et al., 1999) is a more 
promising treatment modality for people with personality disorders than the combination of 
traditional 12-step self-help groups and supportive counseling.  Others believe that the 
personality disorder itself should be the focus of treatment, which, they opine, would improve 
SUD treatment retention, leading to better overall treatment success (Jansson, 2008).   
 Substance use disorders and “severe mental illness.” The literature on other co-
occurring chemical dependency and mental illness seems to lump several disorders into the 
category of severe mental illness (SMI; Mueser  et al., 2009; Pourmand, Kavanaugh, & 
Vaughan, 2004; Xie  et al. 2010).  Severe mental illness covers the Schizophrenia spectrum, 
Bipolar Disorder and Psychosis.  Persons with co-occurring SUDs and SMI often face 
homelessness, episodes of violence, incarceration, and repeated hospitalization (Xie et al., 2010).  
In a study of 116 participants diagnosed with co-occurring SUDs and SMI, nearly 86% of the 
population had achieved at least one period of 6 month abstinence from alcohol, and 35% of 
those who had achieved 6 month remission remained abstinent at the ten year follow up (Xie  et 
al., 2010).  Those who did not achieve short or long term abstinence were more likely to have 
had alcohol dependence rather than alcohol abuse at baseline.  Some of the features that preceded 
abstinence include stabilization of psychiatric symptoms, participation in substance abuse 
treatment programs, competitive employment, and general life satisfaction.  Conversely, those 
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who were less likely to achieve long-term abstinence, had spent additional time in jail or 
psychiatric hospital, and had limited social contact with non-abusers (Xie et al., 2010).  
 Treatment of SMI and SUDs. Dual diagnosis of SMI and SUD can have drastic effects 
on family relationships (Mueser et al., 2009).  Despite the prevalence of family programs within 
both chemical dependency treatment and severe mental illness treatment, there are few family 
programs that address the co-occurring nature of these illnesses.  In studying 108 clients with 
both severe mental illness (again, defined as schizophrenia, schizoaffective disorder, and bipolar 
disorder) and chemical dependency, Mueser  et al. (2008) found that family intervention can be 
effective in both psychiatric symptom stabilization and in reducing the risk of substance relapse.  
The study compared two models of family intervention:  a psychoeducational model and a pilot 
program called Family Intervention for Dual Diagnosis (FIDD).  The primary unique features of 
FIDD include longer family engagement, the addition of family communication skills training, 
family problem solving, and family enhancement of the client’s motivation to remain abstinent 
(Mueser et al., 2008).  Significantly, regardless of the length of the program, those who chose to 
dropout of family intervention did so within the first six weeks, indicating that family members 
who are engaged in client progress will provide additional time and effort into helping the client 
enter a phase of recovery.  Both the psychoeducational groups and FIDD correlated to better 
treatment outcomes due to fewer family conflicts and higher levels of family support (Mueser et 
al., 2010). 
 A similar study challenges the value of family involvement in recovery from co-
occurring SMI and SUD.  In a study of 58 participants with schizophrenia-related DSM-IV 
diagnoses and SUD, the researchers studied family involvement with the participants through 
structured interviews (Pourmund, 2008).  Due to the severity of the participants’ mental illnesses, 
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many of them lived with family members, such as parents and siblings.   Research indicated that 
the presence of expressed emotion, defined as “attitudes and behavior that is likely to induce 
emotional distress” was the most powerful predictor of substance relapse among the cohort (p. 
473).  Since many of the participants lived with family members, the researchers were able to 
gather information relating to over-communication and negative feedback provided by family 
members, which correlated to substance relapse.  
 There is ample literature connecting mental health issues with chemical dependency, 
something that counselors are readily familiar with.  A similar body of literature exists 
connecting severe physical health problems, such as HIV and various cancers with mental health 
issues. 
Co-occurring Severe Physical Illness and Mental Health Disorders 
 The two most prevalent areas of current research on co-occurring physical illness and 
mental illness relate to HIV/AIDS and various forms of cancer.  This literature review focuses on 
these two severe physical illnesses and is in no way a complete representation of manifestations 
of physical illness and mental health related issues. 
 HIV and mental health issues. There are currently 40 million people world-wide and 
1.2 million American’s living with HIV/AIDS (Centers for Disease Control and Prevention, 
2010).  Since the advent of Highly Active Antiretroviral Therapy (HAART) for HIV/AIDS, the 
mortality rate of those living with the virus has dramatically reduced (Ferrando & Freyberg, 
2008).   Instead, HIV has become a chronic, manageable disease, using a regimen of medications 
requiring strict adherence (Reiter, 2000).  Despite the advances in HIV treatment, rates of co-
occurring mental health issues, specifically MDD and Post-Traumatic Stress Disorder (PTSD) 
remain highly prevalent in those HIV positive people being treated with HAART (Eller et al., 
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2010; Ferrando & Freyberg, 2008; Vranceau et al., 2008).  In fact, lifetime rates of current MDD 
in HIV patients is at least twice than that in the general population (Rabkin, Ferrando, 
Jacobsberg, & Fishman, 1997).  Bing et al. (2001) found that over 30% of a nationally 
represented sample of HIV+ individuals met the DSM-IV criteria for either MDD or Dysthymic 
Disorder.   
 Worldwide, the rates of co-morbid HIV disease and depression are even higher.  In a 
study of 1,217 HIV+ individuals in five countries, researchers found that co-occurring rates of 
HIV infection and depression ranged from 35% in Taiwan to 66% in Norway, with an overall 
average of 54% of respondents reporting depressive symptoms (Eller et al. 2010).  Considering 
the ten year differential between the Bing  et al. (2001) and the Eller  et al. (2010) studies, it 
would appear that rates of depression among HIV+ individuals is rising instead of falling, despite 
overall improvements in HIV treatment.  One possible reason for the increase in depression 
among HIV+ individuals is the recent attempt to include more women in the study.  Eller et al. 
(2010) found that HIV+ women were significantly more likely to report symptoms of depression 
then men, something not accounted for in the Bing et al. (2001) study.  Other reasons for 
increases in depression include medication side-effects, social alienation, and self-perception of 
living with HIV for a prolonged period of time (Eller et al., 2010) 
 In addition, income differentiation, poor social support, illness representation, and lower 
medication adherence rates were predictors of increased levels of depression across the study 
(Eller et al., 2010).  Additionally, increased depression correlates with advances in the stage of 
HIV illness (Ferrando & Freyberg, 2008).  Lyketsos et al. (1996) found that depressive 
symptoms increased by 45% in those individuals who developed AIDS-related symptoms versus 
those who remained stable in treatment. Similarly, Rabkin et al. (1997) found significantly 
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higher rates of Dysthymic Disorder in HIV+ patients having a CD4 count less than 500.  Both of 
these studies suggest that both physical symptoms and poor social support were associated with 
higher levels of depressive symptoms (Lyketsos et al., 1996; Rabkin et al., 1997). 
 One of the most significant problems associated with higher levels of depression among 
the HIV+ population is the correlation between depression and low medication compliance 
(Ammassari et al., 2004).  HAART medications are only effective when adherence levels are 
near perfect (Reiter, 2000).   HIV+ patients diagnosed with depression have been found to have 
less than optimal treatment adherence rates (Vranceanu et al., 2008).  Vranceanu et al. (2008) 
studied treatment adherence of 282 persons with HIV disease.  Of the 282, 160 were also 
diagnosed with either depression and/or PTSD per the criteria listed in the DSM-IV. In order to 
substantiate medication adherence, the research team used MEMS Smart Caps, which contain a 
microprocessor that records the date a medication bottle is opened and closed.   For purposes of 
the study a medication dose was considered correct if the MEMS Smart Caps noted that 
medication had been removed within a three hour timespan of the suggested dose time 
(Vranceanu et al., 2008).  In the study, medication adherence was the dependent variable, while 
PTSD and depression were independent variables.  Participants who screened positive for 
depression were “significantly associated” with poor treatment adherence (Vranceanu et al. p. 
318).  Surprisingly, however, those who screened positive for PTSD or a combination of PTSD 
and depression were only marginally associated with diminished treatment adherence. 
 Treating depression and HIV. The literature indicates that depression treatment 
modalities are effective in managing depressive symptoms in some individuals (Ferrando & 
Freyberg, 2008; Ellers et al., 2010).  Psychotropic medications, including fluoxetine, imipramine, 
and other SSRI’s and SNRI’s have been helpful in symptom relief in up to 74% of those studied 
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(Rabkin, Wagner, & Rabkin, 1999).  Caution must be used in prescribing such drugs, however; 
because SSRI’s and HAART drugs use “similar metabolic pathways” which may “inhibit 
metabolism of the SSRI” (Fernando & Freyberg, 2008).  Self-management of depressive 
symptoms has also been found effective (Eller et al. 2010).  Among the most effective strategies 
for managing depressive symptoms without medication are prayer and meditation, physical 
activity, spending time with family and friends, and attending support groups (Eller et al., 2010).  
Unfortunately, there have been few studies that look solely at psychotherapy as a treatment 
modality for co-occurring HIV and depression.  The literature reveals that studies that consider 
individual and group psychotherapy also include psychotropic medication as a variable 
(Ferrando & Freyberg, 2008). 
 Cancer and mental health issues. It was estimated that in 2008, there were nearly 12.7 
million newly diagnosed cancer cases and nearly 7.6 million cancer-related deaths worldwide 
(Ferlay, Bray, Mathers, & Parkin, 2008).  Among cancer patients, it was estimated that 
occurrences of anxiety and depression was nearly twice as high then in the general population 
(Hintz et al., 2010).  MDD was the most commonly diagnosed mental health issue reported by 
cancer patients (Kleiber et al., 2010).  Other common mental health disorders found in the cancer 
population include Generalized Anxiety Disorder (GAD), PTSD, and Social Anxiety Disorder 
(SAD) (Mehnert, Lehmann, Graefen, Huland, & Roch, 2009).  Mental health disorders are more 
likely to occur with specific more severe types of cancer such as hematologic cancer, lung 
cancer, pancreatic cancer, and breast cancer (Fox & Lyon, 2006; Mayr & Schmid, 2010; Priscilla 
et al., 2011).  Research indicated that co-occurring mental health disorders and cancer had 
serious implications on health-related quality of life and on mortality rates (Fox & Lyon, 2006; 
Menhert et al., 2009). 
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 Hematologic cancers, such as leukemia, lymphoma (Hodgkin’s and non-Hodgkin’s), and 
myeloma represent the types of cancers in which mental health issues were most like to co-occur 
(Priscilla  et al., 2011).  In a study of 105 patients with hematologic cancer, 74% of the patients 
reported some form of mental health issue, with MDD and SAD being the most prevalent 
(Priscilla et al. 2011).  Significantly, mental health diagnoses affected health-related quality of 
life across many different spectrums (Fox & Lyon, 2006; Kleiber et al., 2009; Priscilla et al., 
2011).   
 Cancer and quality of life. Priscilla et al. (2011) found negative correlations between 
MDD in cancer patients and five functioning aspects of quality of life, including emotional, 
physical, role, cognitive, and social functioning.  Additionally, physical symptoms such as 
fatigue, sleep disturbance, appetite loss, financial difficulties, and nausea were also correlated 
positively with those cancer patients dually diagnosed with MDD (Priscilla et al.  2011). Similar 
results were reported in patients with lung cancer (Fox & Lyon, 2006).  In a study of 51 patients 
with lung cancer, researchers observed an astounding 98% co-occurrence of MDD, which again 
had positive correlation to a decrease in health-related quality of life (Fox & Lyon, 2006).  Some 
of the contributing factors observed included severity of symptoms, fatigue, and to a lesser 
degree, pain, all of which impacted quality of life and suggests that symptoms of MDD remain 
with lung cancer patients long into survivorship (Fox & Lyon, 2006). 
 In order to determine the effects of cancer on health-related quality of life, 98 patients 
with a variety of cancers who met the DSM-IV criteria for MDD were studied (Kleiber et al., 
2010).   The qualitative study involved in-depth interviews with participants to better understand 
the problems faced by cancer survivors.  The results substantiated earlier claims that co-
occurring cancer and MDD had a negative impact on health-related quality of life.  Of the 
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respondents, 54% reported concerns about cancer relapse and 29% reported concerns about their 
cancer treatment.  As for physical symptoms, 33% reported fatigue, 25% reported sleep 
disturbances, and 21% reported a diminished ability to concentrate.  More than 30% reported 
limitations in functioning, including participating in activities which they used to enjoy.  
Psychologically, 56% reported loss of interest and 55% reported low mood, two of the key 
elements of MDD.  Included in the key elements were the inability to enjoy things and a lack of 
interest in doing things they used to enjoy.  Patients described their mood as “’everything feels 
bleak,’ and ‘there is a dark cloud hanging over me’ (p.65).”  A significant number of respondents 
(61%) also reported difficulties in their interpersonal relationships, including social isolation, 
withdrawal, and marital discord. Furthermore, they found that 65% of the respondents reported 
that they were as concerned for others’ well-being as they were for themselves.  Their concerns 
involved primarily the effects of their disease on those closest to them, such as spouses and 
children.  Respondents questioned whether their family members “’could deal with their illness’” 
and whether their families would be “happy and successful in the future,” or “if they would be 
able to manage financially” (p.66). Patients with hematologic cancer also expressed financial 
concerns as being anxiety producing (Priscilla et al., 2011).  Financial concerns related to the 
family were the predominate factor in cancer patients with SAD. 
 Mental health assessment instruments and cancer. Some theorists claim that depression 
and anxiety should not be used as outcomes related to quality of life in cancer patients (McCabe 
& Cronin, 2010).  They claim that issues of validity and reliability of instruments, such as the 
Beck Depression Inventory (Beck, Steer, & Brown, 1996) and the Hospital Anxiety Depression 
Scale (Zigmond & Snaith, 1983) were not developed to assess outcomes in quality of care 
(McCabe & Cronin, 2010).  Conversely, Mayr and Schmidt (2010) found both the Beck 
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Depression Inventory and the Hospital and Anxiety Depression Scale to be both valid and 
reliable in assessing cancer patients for mental health issues and for helping to determine overall 
health-related quality of life.  As with other co-occurring disorders, however, practitioners and 
theorists disagree as to the cause/effect relationship between cancer and mental health issues.  
Some claim that the effects of cancer treatment alone suffices to produce symptoms that are 
similar in nature to mental health issues, but are not, in and of themselves, mental health 
diagnoses (Mayr & Schmid, 2010; McCabe & Cronin, 2010).  McCabe and Cronin (2010) 
opined that social support following cancer treatment is the most suitable way to assess the 
potential onset of mental health symptoms, and that the quality of such support will often impact 
the patient’s perception of their quality of life.  While Mayr and Schmid (2010) agreed that 
mental health diagnoses should not be associated with cancer patients, they did support the use of 
antidepressant therapy as a means of easing symptomology. 
Co-occurring Severe Physical Illness and Substance Use Disorders 
 Severe physical illnesses, such as HIV/AIDS, Hepatitis C (HCV), and cancers have high 
rates of co-occurring SUDs.  There is significant evidence linking intravenous drug and 
HIV/HCV, while individuals diagnosed with cancer have increased alcohol use and continued 
nicotine use, despite negative consequences.  Some evidence suggests that the development of a 
severe physical illness can be the catalyst to the development of an SUD, while other evidence 
suggests that such illnesses ultimately become factors influencing those with ongoing SUDs to 
stop using drugs.  
 HIV/ Hepatitis C and substance use disorders. HIV and Hepatitis C Virus (HCV) 
share many common attributes.  Both are blood born, chronic, immune-suppressing viruses and 
share certain specific transmission methods, including needle sharing.   HIV can be transmitted 
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sexually, while HCV cannot (Centers for Disease Control and Prevention, 2010). While they are 
not mutually exclusive, they share some common traits and should be considered together as 
they relate to SUDs.  The health issues related to HIV include the development of opportunistic 
infections, such as pneumocystis, toxoplasmosis, and encephalitis, which, if left untreated, will 
likely, lead to death.  Similarly, HCV attacks the liver, causing cirrhosis and liver failure, which 
can also lead to death if left untreated.  
 The literature on co-occurring HIV and SUDs suggests that a combination of social 
customs, mores, religious views, and legislation have impeded efforts to curtail the HIV 
pandemic (Adrian, 2006).  In addition, the interplay between sex and drug use has created a 
continuous, reciprocal cause/effect relationship between SUDs and the spread of HIV.  Thus, it is 
both common for people who become infected with HIV to self-medicate with addictive drugs, 
and equally common for those with addiction disorders to become infected with HIV (Adrian, 
2006).  The same reciprocal relationship exists with co-occurring HCV and chemical 
dependency (Treloar & Rhodes, 2009).  As of 2009, it was estimated that between 30% and 60% 
of injection drug users were infected with HCV, which was commonly attributed to the 
continued practice of sharing needles (Treloar & Rhodes, 2009).   
 Despite the similarities, in co-occurring chemical dependency in HIV and HCV patients, 
the issues are by no means identical.  Since the primary transmission method of HCV is through 
the sharing of needles, HCV presents its own unique set of circumstances. Two key stressors in 
persons with HCV are social stigma and the perceived illness experience (Treloar, 2009).  The 
Treloar study was a qualitative synthesis of 25 English-language, peer reviewed, qualitative 
empirical studies, which focused on the “lived experience” of HCV among injection drug users.  
Social stigma among HCV patients leads to the belief that one has a “spoiled identity,” which is 
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“characterized by a sense of contamination” or lost opportunity (Treloar, 2009, p. 1324-1325).  
Such identity disruption can lead to depression, despair, and disorientation, all of which can 
decrease the user’s quality of life (Matoo, 2008).  
 Lower health related quality life leads to both physical health issues, as well as an 
increased likelihood for substance relapse.   When one compares the impact of HIV on health-
related quality of life to the identified reasons for relapse, one discovers an alarming correlation 
between the two (Adrian, 2006; Matoo, 2008).  An individual’s response to either an HIV or 
HCV diagnosis is likely to cause an increase in the precise stimuli often credited for relapse.  
 HIV and quality of life. Similar to co-occurring cancer and mental illness, one of the 
primary issues in co-occurring HIV/HCV and SUDs is a reduction in health-related quality of 
life (Gjeruldsen, Loge, Myrvang & Opjordsmoen, 2006; Honiden et al., 2006; Perez, et al, 2009; 
Treloar, 2009).  With respect health related quality of life and co-occurring HIV and chemical 
dependency, Honiden et al. (2006) compared the effect that an HIV diagnosis had on the health-
related quality of life in a sample of veterans and university students.  They found that 
participants recently diagnosed with HIV experienced an overall decrease in health-related 
quality of life, including, general health, physical functioning, social functioning, cognitive 
functioning, pain, energy, mental health, health distress and sleep. 
Perez (2009) found a decrease in quality of life in HIV patients due to increased levels of 
depression, anxiety, and social isolation (Perez, 2009). The combination of these emotional 
issues with pain, opportunistic infections, and difficult treatment regimens can cause addiction 
relapse (Adrian, 2006).  In addition, family history of addiction, an increase in high risk sexual 
behaviors, and an increase in undesirable life events can also increase relapse rates (Matoo, 
Chakrabarti & Anjaiah, 2008). Finally, severe chronic stressors, acute stress, and substance 
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availability “have all been identified as important risks” to addiction relapse (Tate, Brown, 
Glasner, Unrod & McQuaid, 2005).   
HCV and quality of life. As with HIV, SUDs lead to lower health-related quality of life 
in HCV patients (Gjeruldsen, Loge, Myrvang & Opjordsmoen, 2006).  In this study, persons 
with co-occurring substance use and HCV scored lower in eight of the nine health related quality 
of life scales than did those people with one or neither of the illnesses. These quality of life 
scales include social and physical functioning, emotional and physical role limitations, mental 
health, vitality and pain. Like people with HIV, people with HCV experienced depression, 
despair and meaning of life questions (Treloar, 2009). 
 Treatment of HIV/HCV and SUD. Despite t, the correlation between HIV and HCV and 
lower health related quality of life treating HIV/and SUD as co-occurring disorders has 
significant benefits to the individual, while treating HCV and SUD as co-occurring disorders had 
fewer benefits..  Research found numerous factors related to both HIV and HCV diagnoses, 
which have a mitigating effect on the potential for relapse.   For instance, one study found that a 
reduction in “family hassles” can have a significant effect on preventing relapse in HIV positive 
African American women (Feaster et al., 2010).  Likewise, a shift in “self-schema,” or assisting 
individuals overcome society’s notion that people with HIV are somehow “bad” had a significant 
correlation with an individual’s desire to change their drug habits and other HIV risk behaviors 
(Avants, Beitel & Margolin, 2005). Finally, within the HIV/AIDS population, participation in 
regular 12-step self-help programs are effective in helping individuals with addiction disorders 
achieve long-term abstinence (Farrell, Gowing, Marsden, Ling & Ali, 2005). 
Unlike the lived experience of persons with co-occurring HIV and SUDs, the HCV 
illness experience not only leads to relapse, but also prevents people from seeking abstinence to 
RELATIONSHIPS BETWEEN DISORDERS  33 
 
begin with (Treloar, 2009).  In a qualitative study (Treloar, 2008), HCV patients tended to 
minimalize or trivialize the disease, if HCV was not actively affecting their health.  To illustrate 
this point, one survey respondent believed that HCV was “no big deal,” and said, “…I don’t care. 
I’ll just keep going the way I am…all you wanna do is get more high (p. 1327).”  The absence of 
symptoms thus has a chilling effect not only on relapse prevention, but also on abstinence itself. 
 Health promotion in drug using communities. One method of curbing relapse and 
increasing mortality in the HCV population involves organizing injection drug users as a 
community (Carruthers, 2007).  Community has been described as an area that is targeted with 
health promotion messages, and needle exchange programs to reduce drug related harm 
(Carruthers, 2007).  In the case of injection drug users, a community consists of persons who 
have a shared interest in using injection drugs.  In other words, members of the injection drug 
community are their own advocates (Carruthers, 2007).  These communities provide services 
such as testing clinics, locally relevant education and information resources, peer education, and 
treatment referral.  Such communities encourage social interaction instead of social isolation to 
challenge group norms and encourage behavior change (Carruthers, 2007). As previously 
discussed, an increase in quality of life, combined with a decrease in social stigma, can lead to 
prolonged abstinence (Treloar, 2009). 
 Multidisciplinary teams. Additionally, the increased use of multidisciplinary teams has 
had a positive impact on both addiction relapse and overall mortality in HCV infected persons 
(Loftis, Matthews & Hauser, 2006). Such teams include primary care physicians, nephrologists, 
nurse practitioners, mental health professionals, and substance abuse specialists.  These teams 
provide education, screening and evaluation for psychiatric and SUDs, coordination of substance 
abuse treatment, coordination of social supports, assessment of liver disease and antiviral 
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therapy.  The multidisciplinary team may also use substitution and maintenance therapy, as well 
as anti-craving agents, all designed to curb addiction relapse (Loftis, 2006).  The end result of 
this coordination of care may curb mortality due to both overdose and HCV. 
Drug replacement therapy. Another primary means of preventing relapse among both 
HIV and HCV patients is the use of drug replacement therapy.  One such therapy involves using 
methadone as a replacement therapy for heroin injection.  In a five year study involving more 
than 5,000 injection drug users, of whom 51% were HIV positive, the introduction of low 
threshold methadone maintenance had a strong, presumptive effect on the decrease in mortality 
rates due to both overdose and HIV (Brugal et al., 2005).  In this case, relapse prevention for 
injection drug users, through drug replacement therapy, had a direct correlation to the decline in 
deaths from both overdose and HIV (Brugal et al. 2005).  Another study found that 43% of a 
randomized population of HIV positive people with heroin addiction did not relapse when being 
treated with a combination of naltrexone and fluoxetine (Krupitsky et al., 2006). 
 In further support of drug replacement therapy as a means of curbing addiction relapse in 
HIV patients, one study found that replacement programs using methadone or buprenorphine led 
to a decrease in both multiple sex partners, and in prostitution (Farrell, 2005).  The researchers 
concluded that substitution treatment allows dependent drug users the opportunity to stabilize 
their physical health and social supports prior to having to face the discomfort of withdrawal, 
ultimately enabling them to adapt to a drug free state (Farrell, 2005).   
 The interplay between co-occurring HIV and SUD has many similarities to co-occurring 
HCV and SUD.  The literature, however, suggests that each illness presents certain unique 
features and should, perhaps, be viewed independently.  Regardless, co-occurrence of either of 
these blood-borne illnesses with SUDs remains a significant health crisis. 
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 Substance use disorders and cancer. Cancer is a pervasive illness that affects many 
different parts of the body.  Much of the literature relates to the effect of continued alcohol and 
tobacco use on individuals with certain types of cancer (Paleri et al., 2010; Webber & Davies, 
2011).  Counselors are likely to encounter cancer patients as part of their practice and should be 
aware of the issues related to a cancer diagnosis.  While much of the literature on this co-
occurring disorder surrounds a limited view of SUDs, the studies present important insight into 
the negative impact of that ongoing SUDs have on this population.  Additionally, research 
suggests that little is being done to screen such patients for co-occurring substance use. 
 Prevalence and survival rates in co-occurring cancer and SUD. Perhaps the most 
significant findings related to co-occurring addiction disorders and cancer concern the decrease 
in survival rates among cancer patients with SUDs. A meta-analysis of comorbidity in head and 
neck cancer reviewed and synthesized data from 77 research studies (Paleri et al., 2010). The 
combined results of the studies indicate that nearly 60% of the patients surveyed in the articles 
had co-occurring SUDs, predominately alcohol and nicotine (Paleri et al., 2010).  Significantly, 
patients who had head or neck cancer and alcohol or tobacco addiction had a much lower 
survival rate than their substance-free cohorts (Paleri et al., 2010).  
Another study followed more than 19,000 men and women who had been patients at a 
Danish outpatient alcohol treatment facility over a 38 year period (Thygesen et al., 2009).  When 
compared to the overall expected cancer rate of the Danish people, those with severe SUDs were 
nearly twice as likely to develop a form of cancer, further bolstering the argument that ongoing 
SUD has a significant effect on the development of cancer.  
Yet another study found a significant risk of oral and pharyngeal cancer among people 
with alcohol and/or tobacco addiction (Pelucchi, Gallus, Garavello, Bosetti, & La Vecchia, 
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2006).  People who were both heavy drinkers and smokers had a 300- times higher risk of oral 
and pharyngeal cancer than those who neither drank nor smoked.   Thus, it can be implied that 
alcohol relapse and subsequent use can have a similar effect on such individuals. 
In those with existing advanced-stage cancers, one study showed that 18% screened 
positive for an alcohol use disorder, which was actually lower than that reported nationally in the 
United Kingdom (Webber & Davies, 2011).   A common alcohol screening instrument was 
administered to 120 participants, all of whom were experiencing numerous physical symptoms 
related to their cancer.  These physical symptoms are similar to those reported in cancer patients 
with co-occurring mental health disorders, including fatigue, drowsiness, and pain  Despite the 
physical symptoms of late stage cancer, less than 20% screened positive for an SUD, suggesting 
that there was some evidence that acute, late stage cancer may have been a significant detractor 
from co-occurring SUD (Webber & Davies, 2011). 
One article did find a correlation of the feelings of helplessness and rage, which often 
accompany a lung cancer diagnosis, and SUD relapse. Specifically, the article stated that feelings 
of “overwhelming helplessness” and “narcissistic rage” are so powerful that they impede one’s 
ability to have concern over other illnesses, ultimately leading to relapse (Tepper, Dodes, Wool 
& Rosenblatt, 2006). The authors agreed that the addicted person is likely to “actively do 
something that he expects will make him feel better (take a drug, gamble, have a sexual 
encounter, and so on)” so that he no longer feels helpless over a co-occurring physical illness (p. 
261). Their findings supported the classic example of using substances or behaviors to cope with 
the emotions that often accompany serious physical illness. 
Screening for SUDs in cancer patients. The most surprising data related to substance 
abuse and cancer concerned the lack of proper substance use screening for both newly diagnosed 
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and advanced cancer patients.  In a review of 51 hospital-based studies involving 618 newly 
diagnosed cancer patients, only three patients were determined to be abusing alcohol, despite 434 
patients having other indicators of alcohol abuse in their medical records (Polednik 2007). The 
study suggested that hospitals were using improper and inadequate screening methods to 
determine whether newly diagnosed cancer patients had co-occurring SUDs.  The author 
suggested that hospitals begin using multiple assessments and screenings for alcohol use in 
newly diagnosed cancer patients in order to provide better cancer treatment (Polednik, 2007). 
Other researchers (Botega et al. 2010) further indicated that hospital admission is an excellent 
opportunity to screen for both psychiatric disorders and chemical dependency.  
 Patients with advanced cancer may also benefit from adequate alcohol screening (Parsons 
et al., 2008).  In a study involving 665 patients with advanced stage cancer, those who screened 
positive for alcoholism using the CAGE questionnaire (Ewing, 1984) manifested greater cancer-
related symptoms.  The researchers concluded that the failure to adequately screen for alcohol 
disorders in patients could lead to inappropriate counseling and pharmacologic mismanagement, 
resulting in increased patient and family suffering (Parsons et al. 2008). 
Summary  
 From the literature, it appears that those who suffer from severe physical illnesses, such 
as HIV, HCV, and various forms of cancer also suffer from SUDs.  Moreover, there is sufficient 
evidence that people with severe physical illnesses also suffer from mental health disorders.  
While there is disagreement as to disease onset and categorization, there is little debate over the 
need to treat mental health issues along with the physical issues. A chronic or severe physical 
illness can develop at any time during one’s developmental process. The literature suggests 
significant research into some areas of co-occurring disorders, but is nearly void of material 
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suggesting the interrelationship between chronic or severe physical illness, mental illness and 
SUDs.  Counselors are trained to view individuals holistically and from a developmental 
standpoint.  This developmental schema separates counselors from other mental health 
professionals.  Since the literature lacks clear examples research aimed chronic or severe 
physical illness, mental illness, and SUDs, this researcher asks the following question:  What is 
the prevalence of mental health diagnoses, substance use disorders and physical illness?  
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Method 
 This quantitative study was a records review of participants that had a current Axis I or 
Axis II mental health diagnosis.  The researcher then determined whether the participants had a 
co-occurring substance use disorder, and finally, whether participants had a co-occurring chronic 
or severe physical Axis III diagnosis.  The research question involved studying possible 
relationships between Axis III diagnoses, mental health diagnoses, and substance use disorders. 
 The study was a retrospective medical records review of 300 participants at a hospital-
based mental health clinic.  Only those participants with an active mental health treatment plan 
were selected.  Demographic information was developed based on age, gender, race, 
occupational status, and years in treatment.  Additional data were collected on each participant’s 
mental health diagnosis, as well as any SUD diagnosis, and any chronic or severe Axis III 
diagnosis. 
 The core focus of the research was to examine whether chronic or severe physical illness 
was related to mental health disorders and/or SUDs.  Descriptive statistics were used to examine 
the data for relationships between Axis III diagnoses and co-occurring mental health diagnoses, 
and substance use diagnoses. 
Setting 
 This study occurred in a major hospital-based mental health clinic in Western New York 
State.  The participants came from both urban and suburban areas.  The clinic accepted 
conventional insurance, as well as Medicaid and Medicare.  Participants in this study were 
referred to the clinic in a variety of ways, including self-referral, referral by primary care 
physicians, other mental health providers, and acute psychiatric centers, including psychiatric 
emergency rooms and local mobile crisis units. 
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Participants 
 A random sample of the medical files of 300 current clients of a hospital-based mental 
health clinic was chosen for evaluation.  The sample was selected based upon the clinic’s 
medical record number, which is a six digit numerical value ending in a three digit combination 
ranging from 001 to 999.  The records are stored on shelving units that divide the records into 
groups of 100, with a total possible sample size of more than 6,000 potential records.   The 
researcher conducted a post hoc power analyses using GPower (Faul & Erdfelder, 1992) with 
power (1 - β) set at 0.80 and α = 05, two-tailed. The analysis revealed a minimum sample size of 
361.  Thus, the sample size was not quite large enough to be generalized to the entire patient 
population.  
 Demographics. Of the sample, 26% (n = 78) were between 18 and 24 years of age, 24%, 
(n = 72) were between 25 and 34, 15% (n = 45) were between 35 and  44, 20.7% (n = 62) were 
between 45 and 54, 9.7 (n = 29) were between 55 and 64, and 4.7% (n = 14) were 65 years of 
age or older. 44% (n = 132) were male, and 56% (n=168) were female.  76.7% (n = 230) 
identified themselves as Caucasian, 17% (n = 51) identified themselves African American or 
Jamaican American, 4.3% (n = 13) identified themselves as Hispanic or Latino, 0.3% (n = 1) 
identified themselves as Asian or Pacific Islander, and 1.7% (n = 5) identified themselves as 
multi-racial.  20.7% (n = 62) reported full-time employment, 11.3% (n = 34) reported part time 
employment, 10.3% (n = 31) reported being either full time students or homemakers, 22.7% (n = 
68) reported that they were totally disabled, either physically or psychologically, 5% (n = 15) 
reported that they were unemployed, but actively seeking employment, 14.7% (n = 44) reported 
that they were unemployed, but not actively seeking employment, 10.3% (n = 31) reported 
receiving welfare or other social services, and 5% (n = 15) reported being retired.  Finally, of the 
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sample, 45.3% (n = 136) reported engaging in their current treatment for one year or less, 14.3% 
(n = 43) reported engaging in their current treatment between 1 and 2 years, 16.3% (n = 49) 
reported engaging in their current treatment between 3 and 5 years, and 24% (n = 72) reported 
engaging in their current treatment for more than 5 years. 
 The demographic data most relevant to this study involved the current employment status 
and the current length of time in treatment, as this information provides potential insight into the 
effects of serious physical illness, mental illness, and chemical dependency on quality of life and 
treatment efficacy and necessity.  The researcher did not have access to the current medical 
condition of the participants, the date of onset of the medical conditions, nor the current 
employment status of the participants, as this was a retrospective review.  Due to these 
limitations, no further analysis of length of time in treatment, or quality of life was completed. 
Intervention and Materials 
 The dependent categorical variable was the Axis I or Axis II mental health diagnosis.  
Each Axis I or Axis II mental health diagnosis was assigned a numerical value based upon the 
diagnosis.  For example, participants with an Axis I mood disorder were assigned the number  
“1” for purposes of the dependent variable, participants with an Axis I anxiety disorder was 
assigned the number “2,”  participants with “other” Axis I disorders  were assigned the number 
“3,” and individuals with any Axis II diagnosis were assigned the number “4.” 
 The independent categorical variables were the Axis I substance use disorder and Axis III 
disorders.  The independent variables were coded in a similar fashion to the Axis I mental health 
diagnoses.  All substance use diagnoses were categorized by number.  Those with alcohol use 
disorders were assigned the number “1,” cannabis use disorders were assigned the number “2,” 
cocaine use disorders were assigned the number “3,” opioid use disorders were assigned the 
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number “4,” amphetamine use disorders were assigned the number “5,” sedative or hypnotic use 
disorders were assigned the number “6.”  
 A similar system of coding was used to describe the independent categorical variable 
Axis III diagnosis.  Participants reporting pain due to a general medical condition were assigned 
the number “1,” those reporting, HIV were assigned the number “2,” those reporting Hepatitis C 
“3,” those reporting pain due to injury or accident were assigned the number “4,” those reporting 
a form of stomach or intestinal issues were assigned the number 5,” those reporting a form of 
cancer were assigned the number “6,” those reporting Multiple Sclerosis were assigned the 
number “7,” those reporting another “chronic” illness were assigned the number “8,” and another 
“serious” illness were assigned the number “9.” 
 The researcher developed the coding system for all of the data.  All data was collected 
from participant files. 
Data Collection 
 The data were collected by reviewing both the “hard copy” of the participants’ medical 
files and the electronic medical records.  The researcher chose 30 random shelving units from 
which to obtain participant files.  Ten files were then selected at random from each of the 30 
shelving units.  Each of the selected files was reviewed for a current, active treatment plan, 
indicating that the participant was a current client at the clinic. Those files that did not have a 
current treatment plan were replaced, and an alternate file was chosen. The percentage of files 
without active treatment plans could not be determined by the researcher.  In groups of 10, each 
medical record was entered into the hospital’s electronic health record system (“Cerner”) to 
determine the presence of a current, active Axis I or Axis II diagnosis, which was the only 
requirement for inclusion in the study.  The Axis I or Axis II mental health diagnosis was then 
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coded and recorded.  Next, the participant’s file was examined for current or past substance use 
disorders.  Since the researcher did not have access to all area chemical dependency treatment 
centers, it is unknown whether each participant’s SUD was truly current or in remission.  The 
researcher chose to include all reported SUDs to be included in the study to better determine 
whether a relationship existed among disorders.  These disorders were then coded and recorded. 
Finally, the participant’s file was examined for current or past Axis III diagnoses, which were 
coded and recorded.  The sampling procedure was approved by the hospital’s institutional review 
board.   
Data Analysis 
 Descriptive statistics were used to evaluate the data collected. It was found that 23.7% (n 
= 71) had been diagnosed with pain due to a general medical condition; 3.7% (n = 11 ) had been 
diagnosed with HIV;  3.3% (n = 10) had been diagnosed with a form of Hepatitis C;  6.7% ( n = 
20) had been diagnosed with pain due to accident or injury;  6.7% (n = 20) had been diagnosed 
with some form of stomach or intestinal illness;  7% (n = 21) had been diagnosed with a form of 
cancer;  0.7% (n = 2) had been diagnosed with multiple sclerosis;  47% (n = 141) had been 
diagnosed with another “chronic” illness; and  4.3% (n = 13),  had been diagnosed with another 
“serious” illness.  “Other” chronic illnesses included:  11% (n = 32) diagnosed with 
Fibromyalgia or “joint pain;”  10% (n = 29) diagnosed with Diabetes;  5.6% (n = 17) diagnosed 
with Hypertension;  5.3% (n = 16) diagnosed with Rheumatoid or Osteoarthritis; 5% (n = 15) 
diagnosed with Chronic Migraine;  4.3% (n = 13) diagnosed with Asthma;  3% (n = 11) 
diagnosed with Thyroid Disease;  3% (n = 11) diagnosed with Heart Disease; and 3% (n = 9) 
diagnosed with Kidney Disease. 
RELATIONSHIPS BETWEEN DISORDERS  44 
 
 The researcher then looked at the participant’s mental health diagnosis.  It was found that 
78.7% (n = 236) had been diagnosed with an Axis I mood disorder;  53.7% (n = 161) had been 
diagnosed with an Axis I anxiety disorder;  8% (n = 24) had been diagnosed with an Axis I 
“other” disorder; and 12.7% (n = 38) had been diagnosed with an Axis II disorder. 
 The researcher then looked at each participant’s file to determine whether they had ever 
been diagnosed with an SUD.  The researcher found that 32.3% (n = 97) had been diagnosed 
with alcohol use disorders;  14% (n = 42) had been diagnosed with cannabis use disorders;  
12.7% (n = 38) had been diagnosed with cocaine use disorders;  17.3% (n = 52) had been 
diagnosed with opioid use disorders;  1.3% (n = 4) had been diagnosed with amphetamine use 
disorders; and  3.3% (n = 7) had been diagnosed with sedative or hypnotic use disorders. 
 Descriptive statistics were analyzed to determine the overall number of individuals with 
Axis III diagnoses that also had concurrent Axis I mental health disorders and Axis I SUDs.  
Further analyses were conducted to compare the most common recurring combinations of co-
occurring disorders across the spectrum of this research. 
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Results 
 The researcher used SPSS version 20 to run frequency analyses to determine descriptive 
statistics and cross tabulations to determine whether relationships existed among the variables 
using Chi Square and Cramer’s V. 
Frequency Analyses 
 Descriptive statistics concerning the participant population are described above and 
yielded few significant results.  Frequency analyses were run to determine the total participant 
population that had any combination of Axis I or Axis II mental health diagnoses, Axis I SUDs, 
and Axis III medical disorders. Results indicated that 66% (n = 198) had both an Axis I or Axis 
II mental health diagnosis and an Axis III medical diagnosis.  50% (n = 151) had both an Axis I 
or Axis II mental health diagnosis and an Axis I SUD.  40 % (n = 119) had an Axis I or Axis II 
mental health diagnosis, and Axis I SUD, and an Axis III medical diagnosis.   
Cross-tabulation Analyses 
 Cross tabulation analyses were run to determine relationships among specific 
combinations of diagnoses.  Chi Square analysis was used to determine whether a significant 
relationship existed (p < .05) and Cramer’s V analysis was used to determine the strength of the 
overall relationship.  Results were then classified in four ways:  Axis I or Axis II mental health 
disorders and Axis III diagnoses;  Axis I SUDs and Axis III diagnoses;  Axis I or Axis II mental 
health diagnoses and Axis I SUDs; and Axis I or Axis II mental health diagnoses, Axis I SUDs, 
and Axis III medical diagnoses.  Significant results were found across all four domains. 
 Mental health disorders and Axis III medical diagnoses. Significant relationships 
were found in several combinations of mental health disorders and medical disorders.  The most 
significant relationships included: Axis I anxiety disorders and Axis III pain due to a general 
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medical condition, X2 (1, n  = 45) = 3.529, p = .04;  Cramer’s V = .108, p = .06; Axis II 
disorders and Axis III pain due to a general medical condition,  X2 (1, N  = 38) = 6.018, p = .015; 
Cramer’s V =.142, p =.014; and Axis II disorders and Axis III stomach/intestinal diagnoses,  X2 
(1, N  =  6) = 5.820, p=.028;  Cramer’s V =.139, p  = .016. 
 SUDs  and Axis III medical diagnoses.  Significant relationships were found in 
numerous combinations of Axis I SUDs and Axis III medical diagnoses.  The most significant 
relationships included:  alcohol use disorders and Axis III Hepatitis C, X2 (1, N  = 7) = 6.708, p = 
.015; Cramer’s V = .15, p = .01;  alcohol use disorders and Axis III stomach/intestinal diagnoses 
X2 (1, N  = 15) = 17.830, p = .001;  Cramer’s V = .224, p = .001;  cocaine use disorders and 
Axis III stomach/intestinal diagnoses X2 (1, N  = 6) = 5.820, p = .028;  Cramer’s V = .139, p = 
.016;  opioid use disorders and Axis III pain due to a general medical condition X2 (1, N = 22) = 
12.099, p = .001;  Cramer’s V = .201, p = .001;  opioid use disorders and Axis III Hepatitis C X2 
(1, N = 7) = 20.025, p = .001;  Cramer’s V = .258, p =.001; and opioid use disorders and Axis 
III pain due to injury or accident X2 (1, N  = 13) = 33.979, p = .001;  Cramer’s V = .337, p = 
.001. 
 Mental health disorders and SUDs.  Significant relationships were found in numerous 
combinations of SUDs and Axis I or Axis II mental health disorders.  The most significant 
relationships include:  Axis I mood disorders and sedative/hypnotic use disorders X2 (1, N  = 8) = 
5.006, p = .024; Cramer’s V = .130, p = .024; Axis I anxiety disorders and cocaine use disorders 
X2 (1, N  = 30) = 11.184, p = .001; Cramer’s V = .193, p = .001; Axis I anxiety disorders and 
opioid use disorders X2 (1, N  = 38) = 9.531, p = .001; Cramer’s V = .178, p = .001; and Axis I 
anxiety disorders and sedative/hypnotic use disorders X2 (1, N  = 9) = 5.492, p = .018; Cramer’s 
V = .135, p = .019. 
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 Mental Health Disorders, Axis I SUDs, and Axis III medical diagnoses.  Several sets 
of significant results were found in combination of the three variables and are summarized in 
Table 1.  Significant results were found in the following categories:  Axis III pain due to general 
medical condition, opiate use disorders, and Axis I mood and anxiety disorders;  Hepatitis C, 
alcohol use disorders, and Axis I mood and anxiety disorders, and Axis II disorders;  Hepatitis C, 
opioid use disorders, and Axis I mood and anxiety disorders, and Axis II disorders; Hepatitis C, 
sedative/hypnotic use disorders, and Axis I mood and anxiety disorders;  Axis III pain due to 
injury or accident, opioid use disorders, and Axis I mood, anxiety and “other” disorders;  
Intestinal/stomach diagnoses, alcohol use disorders, and Axis I mood and anxiety disorders;  and 
Intestinal/stomach diagnoses, cocaine use disorders, and Axis I mood disorders. 
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Table 1 
Relationships among Axis III Diagnoses, SUDs and Axis I and Axis II Mental Health Disorders 
______________________________________________________________________________ 
Diagnoses   N    X
2
  df       p     Cramer’s V      p 
PMC/ Opioid/ 
 Axis I Mood  18 12.099   1    .024      .170    .009           
 Axis I Anxiety 20 12.099   1    .024      .241    .002 
HCV/ Alcohol/ 
 Axis I Mood    6  6.708   1      .015      .180    .004 
 Axis I Anxiety  7  6.708   1    .015       .245               .002 
 Axis II     4  6.708     1            .015       .325    .045 
HCV/Opioids 
  Axis I Mood  7 20.025   1    .001      .302    .001 
 Axis I Anxiety 6 20.025   1    .001      .277    .001 
 Axis II   5 20.025   1    .001      .526    .001 
HCV/ S/H 
 Axis I Anxiety  3 8.198   1    .039      .172    .003 
PAI/ Opioid/  
 Axis I Mood  10 33.979   1    .001      .330    .001 
 Axis I Anxiety 9 33.979   1    .001      .318    .001 
 Axis I Other  3 33.979   1    .001      .798    .001 
Intestinal/ Alcohol/ 
 Axis I Mood  9 17.830   1    .001      .232    .001 
 Axis I Anxiety 8 17.830   1    .001      .230    .003 
Intestinal/ Cocaine/ 
 Axis I Mood   5 5.820   1    .028      .187    .004 
Note. PMC= pain due to general medical condition; HCV= Hepatitis C; S/H = sedative/hypnotics; PAI = pain due to 
accident or injury 
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Discussion 
 This research clearly supports the relationships described in the literature between mental 
illness and SUDs, physical illness and mental illness, and physical illness and SUDs.  The 
additional significant relationships found in this study suggest that there is significant evidence 
of relationships between physical illness, mental illness and SUDs.   
Mental health diagnoses and SUDs 
 Significant research has been conducted on the correlations between mental health issues, 
such as Axis I depression and anxiety disorders and Axis II personality disorders and SUDs (e.g., 
Bowden-Jones  et al., 2004; Conner  et al., 2008;  Davis  et al., 2005; Xie  et al., 2010).  This 
research supports the notion that co-occurring mental health issues and SUDs are commonplace 
in a hospital-based mental health clinic.  Research in this study indicates that 50% of those 
participants who had an Axis I or Axis II mental health diagnosis had a co-occurring SUD.  The 
most prominent mental health diagnoses were Axis I mood disorders (78.7%, n = 236), Axis I 
anxiety disorders (53.7%, n  = 161), and Axis II personality disorders (12.7%,  n = 38).  The 
most prominent SUDs were alcohol dependence (32.3%, n = 97), opioid dependence (17.3%, n = 
52), cannabis dependence (14%, n = 42), and cocaine dependence (12.7%, n = 38).   
 The range of 50% co-occurring mental health/SUD diagnoses found in this study 
supports previous research.  Conner  et al. (2008) found 55% co-occurring mood disorder and 
SUD, while Davis  et al. (2005) found 41% comorbid Axis I mood disorders and SUDs, with 
alcohol being the primary substance used.  Bowden-Jones et al. (2004) found that 37% of 
participants with an Axis II personality disorder had a co-occurring SUD. 
 In the present study, strong relationships exist among those with co-occurring Axis I and 
Axis II mental health diagnoses and SUDs.  These significant relationships include Axis I mood 
disorders and cannabis dependence, Axis I mood disorders and hypnotic/sedative dependence, 
RELATIONSHIPS BETWEEN DISORDERS  50 
 
Axis I anxiety disorders and cocaine dependence, Axis I anxiety disorders and opioid 
dependence, and Axis I anxiety disorders and hypnotic/sedative dependence. 
Mental health diagnoses and axis III medical diagnoses 
 This study also supports the notion that relationships exist between physical illness and 
mental illness.  While much of the literature is focused on “severe” physical illnesses such as 
HIV, HCV, and Cancer, this study shed light on additional illnesses that may play a role in the 
development of mental health issues.  While it is clear from the literature that there is a 
relationship between HIV and mood disorders (e.g. Eller et al., 2010; Ferrando & Freyberg, 
2008; Vranceau et al., 2008), and Cancer and mood disorders (e.g. Fox & Lyon, 2006; Kleiber et 
al., 2009; Priscilla et al., 2011), little research has been conducted into the relationship between 
other chronic illnesses and mental illness. 
 While this study did not find significant relationships between HIV or Cancer and mental 
illness, the sample size of participants reporting these illnesses was relatively low (HIV, 3.7%, n 
= 11, and Cancer, 7%, n = 21).  What this research does suggest is that relationships exist across 
other spectrums of physical illness and mental illness.  Sixty-six percent (n = 198) of the 
participants reported having an Axis I or Axis II mental health diagnosis and an Axis III 
diagnosis.  By far, the most common Axis III diagnoses were “other” chronic illnesses (47%, n = 
141), pain due to general medical condition (23.7% n = 71), pain due to accident or injury (6.7% 
n = 20), and stomach/intestinal issues (6.7%, n = 20).  Small relationships were reported by 
participants having Axis I anxiety disorders and pain due to a general medical condition, Axis II 
personality disorders and pain due to a general medical condition, and Axis II personality 
disorders and stomach/intestinal issues. 
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Axis III medical diagnoses and SUDs 
 There is also significant literature on co-morbid physical illnesses and SUDs (eg., Adrian, 
2006; Honiden et al., 2006 Matoo, 2008; Treolar & Rhodes, 2009).  Again, these studies focused 
primarily on HIV, HCV, and Cancer.  While this study yielded no significant relationships with 
respect to HIV or Cancer, several significant relationships were found between HCV and SUDs.  
In particular, small relationships were found between HCV and alcohol dependence, Cramer’s V 
= .15 and HCV and opioid dependence, Cramer’s V = .258.  The significant relationship 
between HCV and opioid dependence is readily explainable, since heroin is an injectable drug, 
and HCV is often spread through needle sharing (e.g. Carruthers, 2007; Treloar, 2008).  Less 
evident is the rationale behind the correlation between HCV and alcohol dependence, however, it 
is possible that Hepatitis B was incorrectly reported as HCV.  Likewise, one would expect to find 
similar findings with respect to HIV and opioid dependence because HIV is a blood-borne illness 
which can be transmitted through needle sharing in a similar manner as HCV; however, this 
research did not support any significant relationships.   
 This research did, however, suggest significant relationships beyond HIV, HCV, and 
Cancer and SUDs.  In particular, significant relationships exist between stomach/intestinal 
problems and alcohol dependence, Cramer’s V = .244 (small), stomach/intestinal problems and 
cocaine dependence, Cramer’s V = .139 (small), opioid dependence and pain due to general 
medical condition, Cramer’s V = .201 (small), and opioid dependence and pain due to injury or 
accident, Cramer’s V = .337 (moderate).  Further research would need to be conducted as to why 
these relationships exist; however, the researcher can hypothesize that both cocaine and alcohol 
metabolize, in part, in the stomach and intestines, and persons who live with chronic pain, 
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whether due to a medical condition or due to an accident are more likely to be prescribed opioid 
pain medication, leading to dependence. 
Axis III medical diagnoses, mental health diagnoses, and SUDs 
 Finally, and perhaps most significantly, this research looked at relationships between 
physical illness, mental illness, and SUDs, for which there is a dearth of literature available.  
Simple frequency analysis indicated that 40% of the participants had co-occurring medical 
issues, mental health issues, and substance use disorders.  Very little research has been 
conducted as to the implications of physical illness as the threshold for the development of 
mental illness and substance use disorders.  This research provides initial empirical evidence that 
a relationship exists among the three domains.  Table 1 above summarizes the significant 
relationships reported by the study participants.   
 Areas of interplay among the three domains include pain due to a general medical 
condition, mood disorders, anxiety disorders, and opioid dependence, leading the researcher to 
question what the “threshold” issue really was.   Similar relationships were reported among 
participants who indicated pain due to accident or injury, Axis I mood and anxiety disorders, and 
opioid dependence.   In addition, participants reported multiple instances of HCV, Axis I mood 
and anxiety disorders, Axis II disorders, and alcohol, opioid and sedative/hypnotic dependence, 
lending credence to the argument that HCV may be a threshold physical illness related to the 
development of both mental illness and SUDs.  Additional research would need to be conducted 
to support this notion; since this researcher was unable to conclude which diagnosis came first.  
Finally, participants reported significant relationships among stomach/intestinal issues, Axis I 
mood and anxiety disorders, and alcohol and cocaine dependence. 
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Implications for Mental Health Counselors 
 Mental Health Counselors rely on strengths-based, client centered care.  While the 
medical model of care, utilized by much of the mental health service delivery system, plays a key 
role in the mental health counselor’s duties, counselors often move beyond the medical model to 
look for issues that occur along one’s developmental spectrum that give rise to distress.   
Managed care is a reality for mental health counselors.  Thus, mental health counselors must be 
skilled in DSM-IV based diagnostics.  Despite the requirements of managed care, unlike other 
mental health professionals, mental health counselors prefer to utilize the DSM-IV as one tool in 
accurately diagnosing clients.  Developmental characteristics and milestones are equally as 
important to mental health counselors in evaluating clients for treatment. 
 One aspect along the developmental spectrum that could prove important in determining 
the onset of psychological symptoms or SUDs is physical illness.  Physical illness can affect 
one’s quality of life in a variety of areas of functioning, leading to symptoms that mimic 
depression or anxiety.  Likewise, the sudden onset of a severe or chronic physical illness may 
reduce an individual’s level of coping skills, which may lead a client into substance abuse or 
dependence as a means of coping. 
 Mental health counselors are not medical doctors.  As such, when clients come in for 
mental health services, it is rare that medical diagnoses are discovered at the time of evaluation, 
unless the client is forthright in their medical history, or unless the counselor spends a significant 
amount of time discussing medical conditions.  While most mental health evaluations include a 
brief medical history, rarely do clinicians discuss history and onset of physical illness as part of 
the overall mental health diagnostic impression.  As such, mental health counselors are unable to 
determine whether physical illness is the threshold issue on the developmental spectrum that 
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causes an individual to develop mental distress or SUDs.  If mental health counselors had better 
insight into the originating factors that led to the development of mental illness and/or SUDs, it 
is possible that alternative treatment protocols would be beneficial. 
 Absent a clear understanding of the client’s physical illness, including type of illness, 
severity of illness, effect of illness on quality of life, and date of onset of illness, mental health 
counselors are basing diagnostic impressions on only one part of the individual.  Obtaining 
additional information about physical illnesses would allow counselors to treat clients more 
holistically, and may allow counselors to free themselves of some of the rigidity found in the 
DSM-IV.  Physical illness and its effects on quality of life may presuppose mental health 
diagnostic criteria, freeing the mental health professional to pursue different diagnostic and 
treatment regimen. 
Study Limitations 
 Several limitations prevented the researcher from making specific conclusions about 
physical illness as the threshold issue for the development of mental illness and chemical 
dependency.  This study was conducted during six months of the researcher’s Master’s 
internship.  While the sample was random, the participant files did not contain the complete 
medical history of each individual.  As such, the date of onset of Axis III medical conditions 
could not be determined by the researcher. Thus, whether the Axis III medical illness was the 
“threshold” issue for the development of Axis I and Axis II conditions could not be determined.  
This study was also limited by the number of participants reporting incidents of cancer, HIV, and 
HCV, about which, most of the literature describes.  More complete data would likely be 
available by obtaining participants from specialized clinics treating these illnesses. 
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 Another limitation of this study was the subjective definition assigned by the researcher 
to the term, “chronic” or “severe” physical illness.  Since this study involved a retrospective 
medical records review, the researcher could not determine the whether the physical illness was 
in remission.  The same is true of participants with SUDs.  This additional information would 
have been helpful to help determine each participant’s “threshold issue.” 
Implications for Further Research 
 The primary implication determined by this study was the existence of strong 
relationships among physical illness, mental illness, and SUDs.  Future research into this area 
should be directed toward determining the “threshold issue.”  Research into the onset dates of 
physical illness, mental health diagnosis, and SUD diagnosis would prove helpful in making this 
determination.  Access to complete medical files and access to multiple chemical dependency 
treatment programs may reinforce the initial findings described herein.  Additional quantitative 
sources, such as onset dates could be used, or in-depth qualitative analysis could be used to help 
researchers better determine the “threshold issue.” 
 Another broad implication for further research involves the notion of pain, whether due to 
general medical condition, accident or injury, or pain “syndromes” such as Fibromyalgia as the 
threshold for the development of co-occurring mental health disorders and SUDs.  In this study, 
many participants reported pain as their primary Axis III diagnosis. 30% (n = 91) reported some 
form of chronic pain as an Axis III condition.  Other chronic illnesses, including diabetes, heart 
disease, and kidney disease are also ripe areas for research into Axis III medical conditions as the 
threshold for the development of mental illness and SUDs. 
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Conclusion 
 While the scope and breadth of this research cannot determine the “chicken or the egg” 
phenomena, strong relationships exist among three significant domains of participant care.  
Counselors should be aware of the research implications in this study and use caution in over-
diagnosing mental health disorders without first looking at Axis III medical conditions as the 
potential threshold issue.  Counselors would be wise to spend some additional time discussing 
the onset of physical illness with clients to help determine whether mental health and substance 
use issues are better explained as developmental phenomena, instead of DSM-IV diagnoses.  
Counselors would also benefit from developing strong relationships with primary care 
physicians, nurse practitioners, and medical case managers to better understand the origin of a 
client’s distress. 
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